Novozymes A/S (CPH:NSIS.B)
358.40
+7.70 (2.20%)
Mar 24, 2026, 4:59 PM CET
Novozymes Revenue
In the year 2025, Novozymes had annual revenue of 4.16B EUR with 8.45% growth. Novozymes had revenue of 996.60M in the quarter ending December 31, 2025, with 1.55% growth.
Revenue
4.16B EUR
Revenue Growth
+8.45%
P/S Ratio
5.38
Revenue / Employee
369.14K EUR
Employees
11,263
Market Cap
166.98B DKK
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.16B | 324.10M | 8.45% |
| Dec 31, 2024 | 3.83B | 1.43B | 59.58% |
| Dec 31, 2023 | 2.40B | 46.92M | 1.99% |
| Dec 31, 2022 | 2.36B | 344.63M | 17.14% |
| Dec 31, 2021 | 2.01B | 122.03M | 6.46% |
| Dec 31, 2020 | 1.89B | -34.05M | -1.77% |
| Dec 31, 2019 | 1.92B | -455.38K | -0.02% |
| Dec 31, 2018 | 1.92B | -28.45M | -1.46% |
| Dec 31, 2017 | 1.95B | 44.03M | 2.31% |
| Dec 31, 2016 | 1.91B | 28.53M | 1.52% |
| Dec 31, 2015 | 1.88B | 204.34M | 12.20% |
| Dec 31, 2014 | 1.67B | 99.58M | 6.32% |
| Dec 31, 2013 | 1.58B | 69.01M | 4.58% |
| Dec 31, 2012 | 1.51B | 92.11M | 6.51% |
| Dec 31, 2011 | 1.41B | 109.59M | 8.40% |
| Dec 31, 2010 | 1.30B | 166.75M | 14.66% |
| Dec 31, 2009 | 1.14B | 44.95M | 4.11% |
| Dec 31, 2008 | 1.09B | 92.14M | 9.21% |
| Dec 31, 2007 | 1.00B | 88.28M | 9.68% |
| Dec 31, 2006 | 912.26M | 70.85M | 8.42% |
| Dec 31, 2005 | 841.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| A.P. Møller - Mærsk | 343.41B |
| DSV A/S | 247.33B |
| Vestas Wind Systems | 140.57B |
| Carlsberg | 89.10B |
| Ørsted | 73.24B |
| Danske Bank | 56.55B |
| Tryg A/S | 43.00B |
| Coloplast | 27.89B |
Novozymes News
- 1 year ago - Top 3 global stocks poised for 40% gains by 2025 - Invezz
- 2 years ago - Invitation to an extraordinary shareholders' meeting of Novozymes A/S - GlobeNewsWire
- 2 years ago - The Novozymes Report 2023 - GlobeNewsWire
- 2 years ago - Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed - GlobeNewsWire
- 2 years ago - Legacy Novozymes delivers solid last full-year results - GlobeNewsWire
- 2 years ago - Completion of the combination between Novozymes and Chr. Hansen - GlobeNewsWire
- 2 years ago - The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner - GlobeNewsWire
- 2 years ago - All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen - GlobeNewsWire